Belgium's Galapagos NV says that GlaxoSmithKline ($GSK) is prepping a Phase II study of GSK2586184 (formerly GLPG0778)--its JAK1 inhibitor--for ulcerative colitis. The advance triggers a $46 million milestone payday for Galapagos, which partnered with GSK on the program in early 2012. "Galapagos has discovered multiple JAK inhibition molecules, three of which have reached the clinic," said Onno van de Stolpe, CEO of Galapagos. Release